MENU
+Compare
CYCN
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$2.99
Change
+$0.08 (+2.75%)
Capitalization
8.1M

CYCN Cyclerion Therapeutics Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products for serious and orphan diseases

Industry Biotechnology
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CYCN with price predictions
Jan 08, 2025

CYCN in -4.56% downward trend, declining for three consecutive days on January 06, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CYCN declined for three days, in of 304 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 76 cases where CYCN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 02, 2025. You may want to consider a long position or call options on CYCN as a result. In of 110 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for CYCN moved above the 200-day moving average on January 03, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCN advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.988) is normal, around the industry mean (14.744). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). CYCN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (38.462) is also within normal values, averaging (264.079).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYCN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CYCN is expected to report earnings to rise 75.00% to -28 cents per share on August 08

Cyclerion Therapeutics CYCN Stock Earnings Reports
Q2'23
Est.
$-0.28
Q1'23
Beat
by $0.14
Q4'22
Beat
by $0.12
Q3'22
Beat
by $5.96
Q2'22
Missed
by $0.01
The last earnings report on May 11 showed earnings per share of -15 cents, beating the estimate of -30 cents. With 12.46K shares outstanding, the current market capitalization sits at 8.10M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products for serious and orphan diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
245 First Street
Phone
+1 857 327-8778
Employees
1
Web
https://www.cyclerion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HEOMX16.630.12
+0.73%
Hartford Climate Opportunities A
CTSIX39.020.10
+0.26%
Calamos Timpani Small Cap Growth I
EEMHX7.930.02
+0.25%
MFS Emerging Markets Equity Research R6
CIPMX23.290.05
+0.22%
Champlain Mid Cap Adv
VWYFX44.420.04
+0.09%
Voya Small Cap Growth A

CYCN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with BLUE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then BLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
+2.75%
BLUE - CYCN
44%
Loosely correlated
+1.09%
HRTX - CYCN
33%
Poorly correlated
+3.82%
GDTC - CYCN
31%
Poorly correlated
-0.42%
FATE - CYCN
29%
Poorly correlated
+1.60%
FRES - CYCN
28%
Poorly correlated
N/A
More